Etanercept Survival in Elderly Population
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 70
- 试验地点
- 5
- 主要终点
- Ineffectiveness of treatment in localized lesions in patients with etanercept treatment
研究概览
简要总结
Evaluate the 3-year survival of etanercept in patients over 60 years with psoriasis in moderate / severe plaque and the reasons that led to the abandonment. Besides factors that might have had a positive or negative influence on adherence to treatment and analysis of efficacy (PASI 75) and safety will be identified.
All variables were collected through retrospective review of medical records of patients dermatology unit are made.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with moderate / severe psoriasis (with / without psoriatic arthritis,PAs) defined by: PASI(Psoriasis Area and Severity Index)> 10 and / or BSA(Body Surface Area)> 10% and / or DLQI(Dermatology Life Quality Index)> 10
- •PASI> 10 and / or BSA(Body Surface Area)> 10% and / or DLQI(Dermatology Life Quality Index)> 10
- •Over 60 years of age at the start of treatment
- •Receiving etanercept at any time
- •Available history in the Dermatology
排除标准
- •Patients with insufficient clinical data in the medical record
结局指标
主要结局
Ineffectiveness of treatment in localized lesions in patients with etanercept treatment
时间窗: 24 weeks(duration of treatment with etanercept)
Despite having achieved a good response PASI no improvement in critical injuries
Secondary ineffectiveness in patients with etanercept treatment
时间窗: 24 weeks (duration of treatment with etanercept)
Number of participants with Poor adherence to treatment with etanercept",
primary ineffectiveness in patients with etanercept treatment
时间窗: 24 weeks
Number of participants not achieve PASI 75 response at 24 weeks
次要结局
- number of participants with Poor adherence to treatment with etanercept(24 weeks)
- number of participants with Conditions requiring hospitalization and / or surgery(24 weeks)
- Number of participants with adverse events during treatment with etanercept(24 weeks)
- Number of participants with disease remission(24 weeks)